Jubilant Pharmova Q2 FY27 Revenue Up 21% to ₹2,370 Cr; PAT at ₹31 Cr
Jubilant Pharmova reported Q2 FY27 revenue of ₹2,370 Cr, a 21% YoY increase, with PAT at ₹31 Cr. H1 FY27 revenue was ₹4,599 Cr. The company announced a $67 million (approx. ₹555 crore) capex for Radiopharma capacity expansion and raised ₹800 Cr via NCDs. They expect H2 FY27 margins to improve to mid-teens.
The announcement includes key financial results, significant capex plans for capacity expansion, and a positive outlook for future performance, which are material events for investors.
The company reported significant revenue growth across segments and provided a positive outlook for the second half of the fiscal year, including expected margin improvements. The capex announcement and successful NCD raise further indicate positive future prospects.
Jubilant Pharmova Limited announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a 21% year-on-year revenue growth for Q2 FY2027, reaching ₹2,370 Crores, driven by strong performance across all business segments, notably CDMO Sterile Injectables, Allergy, Radiopharma, and Generics.
EBITDA for the quarter stood at ₹255 Crores, and Profit After Tax (PAT) was ₹31 Crores. For the first half of FY2027 (H1 FY2027), revenue grew by 19% to ₹4,599 Crores, with EBITDA at ₹523 Crores and PAT at ₹87 Crores. The company noted that EBITDA margins declined year-on-year primarily due to the unavailability of high-margin SPECT radiopharma products and higher operating expenses, including remediation costs at the CMO Montreal facility.
Key business updates include a capex of $67 million (₹555 crore approximately) to double manufacturing capacity for Radiopharma, driven by growth in Ruby-Fill. The Spokane sterile injectables facility received a VAI status, and a Master Services Agreement was signed with a large pharma customer for an oncology product. The company also successfully raised non-convertible debentures of ₹800 Crores.
Looking ahead to H2 FY2027, Jubilant Pharmova expects continued revenue growth momentum and margin improvement, with average H2 margins anticipated to be in the mid-teens. This is supported by the stabilization of SPECT product supplies from Montreal, increased production volumes in Allergy Immunotherapy, continued traction on new lines in Sterile Injectables, and new product launches in Generics.
The company presented clinical data for its novel molecule JBI-802 at the SOHO annual meet and plans to present initial data at the American Society of Hematology conference in December 2026. The company reiterated its vision to achieve zero debt by 2030, supported by expected reductions in capex from FY2028 and improved cash flows from new launches and operational efficiencies.
What to do with a filing like this
Jubilant Pharmova Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Pharmova Limited. Read the original for the full detail.